Maxigen BiotechTPE:1783 +2.70%87 Days Payable is 126.29 as of Dec. 2025, which is 140% above its 10-year median of 52.71. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.11 (Significantly Undervalued). Among 795 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 64.65% on this metric.
The historical rank and industry rank for Maxigen Biotech's Days Payable or its related term are showing as below:
TPE:1783'
s Days Payable Range Over the Past 10 Years
Min: 48.9 Med: 52.71 Max: 100.74
Current: 99.37
During the past 13 years, Maxigen Biotech's highest Days Payable was 100.74. The lowest was 48.90. And the median was 52.71.
TPE:1783's Days Payable is ranked better than 64.65% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs TPE:1783: 99.37
Maxigen Biotech's Days Payable
increased
from Dec. 2024 (81.03) to Dec. 2025 (126.29).
It may suggest that Maxigen Biotechdelayed paying its suppliers.
Maxigen Biotech Days Payable Related Terms
Maxigen Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Maxigen Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a Days Payable of 126.29 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Maxigen Biotech and its competitors. This is 140% above median its historical median of 52.71. Over the past decade, Maxigen Biotech's Days Payable has ranged from 48.90 to 100.74. According to the industry distribution chart, Maxigen Biotech ranks #281 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 35.3%.
Is Maxigen Biotech's Days Payable too high?
Maxigen Biotech's current Days Payable of 126.29 is 140% above median its 10-year median of 52.71. Over the past 10 years, this metric has ranged from a low of 48.90 to a high of 100.74. The Medical Devices & Instruments industry median Days Payable is 68.07. Maxigen Biotech's value of 126.29 is 85.5% above this industry median. Based on the distribution chart, Maxigen Biotech ranks #281 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #281 out of 795 companies for Days Payable. This puts Maxigen Biotech in the upper half of its industry. The industry median Days Payable is 68.07. Maxigen Biotech's value of 126.29 is 85.5% above this benchmark. Historically, Maxigen Biotech's own Days Payable has ranged from 48.90 to 100.74 over the past decade. While the company's 10-year median is 52.71 vs. the industry median of 68.07, Maxigen Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current Days Payable of 126.29 is 85.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current Days Payable is 126.29, which is 140% above median its own 10-year median of 52.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.11, compared to a current price of NT$39.90 — trading 34.7% below its estimated fair value. The current Days Payable is 126.29, which is 140% above median its 10-year median of 52.71 and 85.5% above the Medical Devices & Instruments industry median of 68.07. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Days Payable is 126.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$39.90 is trading 34.7% below its estimated GF Value™ of NT$61.11.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
Days Payable: 126.29 (140% above median its 10-year median of 52.71)
GF Value™: NT$61.11 vs. price of NT$39.90 (34.7% below fair value)
Industry Position: 85.5% above the Medical Devices & Instruments median (#281 of 795)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
